Quanterix Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Quanterix Corporation on September 8, 2022, regarding events occurring on September 6, 2022. The filing discloses the appointment of a new senior executive officer and details the associated compensatory arrangements.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes
The primary material change reported is the appointment of Daniel Pikora as Chief Operating Officer (COO), effective September 6, 2022. Mr. Pikora previously served as Executive Vice President, Research Business, having joined the company in May 2022.
Management Commentary and Compensation Details
The filing outlines the terms of Mr. Pikora's employment agreement dated March 28, 2022:
- Base Salary: $415,000 annually.
- Performance Bonus: Target of up to $249,000 annually, beginning with the 2022 performance year.
- Sign-on Payment: $500,000 cash payment, with 50% subject to repayment if employment is voluntarily terminated before May 2, 2023.
- Initial Equity Award: 51,300 restricted stock units (RSUs) vesting over three years (33% on May 2, 2023; 33% on May 2, 2024; 34% on May 2, 2025).
- Future Equity: Eligibility for an annual equity grant with a target fair value of up to $650,000 in the next long-term equity award cycle.
- Termination Benefits: In the event of termination without cause or resignation for good reason, the executive receives six months of base salary, a pro-rated bonus, health benefits continuation, and acceleration of RSUs vesting on May 2, 2023. Full acceleration of all unvested RSUs occurs if termination happens within 90 days prior to or 12 months following a change-in-control.
Investor Verification Checklist
- Verify the total potential annual compensation value including base, bonus, and equity targets.
- Review the attached Exhibit 10.1 (Employment Agreement) for specific restrictive covenants and release requirements.
- Confirm the vesting schedule and conditions for the 51,300 RSUs and future equity grants.
- Assess the impact of the $500,000 sign-on payment on immediate cash flow and the repayment clause conditions.